Investigation of molecular forms of ANP and BNP in patients with heart failure treated with ACE inhibitor and following switch to sacubitril valsartan.
University of Leicester
Duration of Study in the UK
2 years, 0 months, 6 days
The recent PARADIGM-HF trial in chronic heart failure (CHF) demonstrated the superiority of the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril valsartan (Entresto), compared to the current gold-standard ACE (Angiotensin Converting Enzyme)inhibitor, on the composite end point of cardiovascular mortality or hospitalisation for heart failure. The mechanism of action of Entresto is thought to include increase in plasma levels of natriuretic peptides (NP); however the precise changes in circulating NP levels elicited by Entresto are unknown; thus the precise mechanism by which Entresto confers prognostic benefit in CHF is unclear. This observational cohort study will investigate circulating plasma levels of natriuretic peptides in patients taking an ACE inhibitor and then after switch to Entresto. The study period will run for a period of 4-6 weeks however the switch to Entresto will be clinically indicated, and not made for the purpose of this research.
East Midlands - Leicester Central Research Ethics Committee
Date of REC Opinion
11 May 2017